Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.

[1]  R. Schmid,et al.  New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness , 2019, Front. Oncol..

[2]  C. Guerra,et al.  Pancreatic Ductal Deletion of Hnf1b Disrupts Exocrine Homeostasis, Leads to Pancreatitis, and Facilitates Tumorigenesis , 2019, Cellular and molecular gastroenterology and hepatology.

[3]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[4]  Nicholas D. Camarda,et al.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. , 2018, Cancer discovery.

[5]  Robert E Denroche,et al.  Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. , 2018, Cancer discovery.

[6]  M. Barbacid,et al.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. , 2018, Cold Spring Harbor perspectives in medicine.

[7]  P. Grippo,et al.  Pancreatic cancer subtypes: a roadmap for precision medicine , 2018, Annals of medicine.

[8]  M. Barbacid,et al.  c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. , 2018, Cancer cell.

[9]  Mathias J Friedrich,et al.  Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes , 2018, Nature.

[10]  D. Pisano,et al.  Nextpresso: Next Generation Sequencing Expression Analysis Pipeline , 2017, Current Bioinformatics.

[11]  M. Karin,et al.  Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. , 2017, Cancer cell.

[12]  F. Gnad,et al.  Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous , 2017, Proceedings of the National Academy of Sciences.

[13]  J. Iovanna,et al.  Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts , 2017, Cell reports.

[14]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[15]  M. Barbacid,et al.  A Braf kinase-inactive mutant induces lung adenocarcinoma , 2017, Nature.

[16]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[17]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[18]  Bo Wang,et al.  Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. , 2016, JAMA internal medicine.

[19]  Brandon Da Silva,et al.  NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer , 2016, Cell.

[20]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[21]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[22]  S. Robertson,et al.  Expanding the power of recombinase-based labeling to uncover cellular diversity , 2015, Development.

[23]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[24]  M. Hidalgo,et al.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.

[25]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[26]  M. Burotto,et al.  Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. , 2015, The oncologist.

[27]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[28]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[29]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[30]  J. Ahn,et al.  Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21 , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[32]  Raul Rabadan,et al.  SAVI: a statistical algorithm for variant frequency identification , 2013, BMC Systems Biology.

[33]  W. Placek,et al.  Acneiform rash during lung cancer therapy with erlotinib (Tarceva®) , 2013, Postepy dermatologii i alergologii.

[34]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[35]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[36]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[37]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[38]  K. Horiuchi,et al.  Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand–dependent terminal keratinocyte differentiation , 2012, The Journal of experimental medicine.

[39]  M. Barbacid,et al.  What we have learned about pancreatic cancer from mouse models. , 2012, Gastroenterology.

[40]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[41]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[42]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[43]  E. Moding,et al.  Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice , 2011, Disease Models & Mechanisms.

[44]  M. Barbacid,et al.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.

[45]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[46]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[47]  S. Pease,et al.  Advanced protocols for animal transgenesis : an ISTT manual , 2011 .

[48]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[49]  David A Gewirtz,et al.  Toxicity issues in cancer drug development. , 2010, Current opinion in investigational drugs.

[50]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[51]  M. Hidalgo.  Pancreatic cancer. , 2010, The New England journal of medicine.

[52]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[53]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[54]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[55]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[56]  M. Sibilia,et al.  The EGF receptor is required for efficient liver regeneration , 2007, Proceedings of the National Academy of Sciences.

[57]  A. Bhandoola,et al.  Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. , 2007, Cell stem cell.

[58]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[60]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[62]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[63]  P. Chambon,et al.  A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse , 2003, Nature Biotechnology.

[64]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[65]  E. Wagner,et al.  Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis , 2001, The Journal of experimental medicine.

[66]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.